Evidence map›Paper›PMID 38332694›Full record

ArticleCurrent medicinal chemistry2024

Potential Role of Bone Metabolism Markers in Kidney Transplant Recipients.

Flávia Maria Borges Vigil, Pedro Alves Soares Vaz de Castro, Ursula Gramiscelli Hasparyk, Victória Soares Bartolomei, Ana Cristina Simões E Silva

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Flávia Maria Borges VigilInterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID 0000-0002-0651-3566
Pedro Alves Soares Vaz de CastroInterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID 0000-0002-1183-7610
Ursula Gramiscelli HasparykInterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID 0000-0002-5037-4751
Victória Soares BartolomeiInterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID 0000-0002-8667-131X
Ana Cristina Simões E SilvaInterdisciplinary Laboratory of Medical Investigation, Unit of Pediatric Nephrology, Faculty of Medicine, Federal University of Minas Gerais (UFMG), Belo Horizonte, Brazil.ORCID 0000-0001-9222-3882
Universidade Federal de Minas Gerais · BR

Funding

Brazilian National Council of Research Development (CNPq) Grant No. 302153/2019-5
6 · The paper itself

Abstract

backgroundThe impact of treatments, suppressing the immune system, persistent hyperparathyroidism, and other risk factors on mineral and bone disorder (MBD) after kidney transplantation is well-known. However, there is limited knowledge about their effect on bone metabolism biomarkers. This study aimed to investigate the influence of kidney transplant on these markers, comparing them to patients undergoing hemodialysis and healthy individuals.

methodsIn this cross-sectional study, three groups were included: kidney transplant patients (n = 57), hemodialysis patients (n = 26), and healthy controls (n = 31). Plasma concentrations of various bone metabolism biomarkers, including Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23, were measured. Associations between these biomarkers and clinical and laboratory data were evaluated.

resultsA total of 114 patients participated. Transplant recipients had significantly lower levels of Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, sclerostin, and fibroblast growth factor 23 compared to hemodialysis patients. Alkaline phosphatase levels positively correlated with osteopontin (r = 0.572,

conclusionKidney transplantation significantly improves mineral and bone disorders associated with end-stage kidney disease by modulating MBD markers and reducing bone metabolism markers, such as Dickkopf-related protein 1, osteoprotegerin, osteocalcin, osteopontin, and sclerostin. Moreover, the panel of bone biomarkers effectively predicted hypercalcemia and dyslipidemia in transplant recipients.

Indexed as

BiomarkersBone and BonesFibroblast Growth Factor-23Kidney TransplantationOsteocalcinAdaptor Proteins, Signal TransducingAdultCross-Sectional StudiesFemaleFibroblast Growth FactorsHumansIntercellular Signaling Peptides and ProteinsMaleMiddle AgedOsteopontinOsteoprotegerinAdaptor Proteins, Signal TransducingBiomarkersDKK1 protein, humanFibroblast Growth Factor-23Fibroblast Growth FactorsIntercellular Signaling Peptides and ProteinsOsteocalcinOsteopontinOsteoprotegerinSOST protein, humanbiomarkers.bone metabolismchronic kidney diseasehemodialysisKidney transplantationrenal osteodystrophy

Identifiers

PMID38332694
OpenAlexW4391687039

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.